4205-05-4

Basic information

• Product Name: 2-(4-CHLORO-PHENYL)-1H-IMIDAZOLE
• Synonyms: 2-(4-CHLORO-PHENYL)-1H-IMIDAZOLE;2-(4-Chlorophenyl)imidazole
• CAS NO: 4205-05-4
• Molecular Formula: C₉H₇ClN₂
• Molecular Weight: 178.62
• Mol File: 4205-05-4.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 365.5 °C at 760 mmHg
• Flash Point: 206.3 °C
• Appearance: /
• Density: 1.292 g/cm³
• Vapor Pressure: 3.29E-05mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(4-CHLORO-PHENYL)-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-CHLORO-PHENYL)-1H-IMIDAZOLE(4205-05-4)
• EPA Substance Registry System: 2-(4-CHLORO-PHENYL)-1H-IMIDAZOLE(4205-05-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• Hazardous Substances Data: 4205-05-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H7ClN2/c10-8-3-1-7(2-4-8)9-11-5-6-12-9/h1-6H,(H,11,12)

Upstream product

• 108-90-7 chlorobenzene 
• 50846-98-5 2-Diazo-2H-imidazole 
• 288-32-4 1H-imidazole 
• 106-47-8 4-chloro-aniline 
• 131543-46-9 Glyoxal 
• 104-88-1 4-chlorobenzaldehyde 
• 27429-86-3 2-(3-chlorophenyl)-4,5-dihydro-1H-imidazole 
• 13623-52-4 2-(4-chlorophenyl)-2-imidazoline 
• 122-01-0 4-chloro-benzoyl chloride 
• 107-15-3 ethylenediamine 
• 623-03-0 4-Cyanochlorobenzene 

Downstream Products

• 1160826-45-8 C₁₆H₁₀ClN₃O₃ 
• 1160826-53-8 C₁₆H₁₀BrClN₂O 
• 1253697-54-9 2-(4-chlorophenyl)-1-(phenylsulfonyl)-1H-imidazole 
• 1253697-97-0 ABI-286 
• 1253697-73-2 (2-(4-chlorophenyl)-1-(phenylsulfonyl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone 
• 65004-59-3 2-(4-chlorophenyl)-4-chlorosulfonylimidazole 

Relevant articles and documents

NOVEL IMIDAZOLE DERIVATIVE, AND ORGANIC EL ELEMENT PREPARED THEREWITH

PROBLEM TO BE SOLVED: To provide a novel imidazole derivative that emits light with high efficiency, and an organic EL element prepared therewith. SOLUTION: The present invention provides a benzoimidazophenanthridine compound represented by the following

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.